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Abstract. The drug accumulation of a human multidrug
resistance 1 (mdr1) gene-transfected mouse lymphoma cell line
and a multidrug resistance protein (MRP)-expressing human
breast cancer cell line MDA-MB-231 was compared in the
presence of sixteen flavonoids and five isoflavonoids. The
expression of the 170-kDa P-glycoprotein (P-gp) (MDR1) and
190-kDa multidrug resistance protein (MRP) in both cell lines
was confirmed by immunocytochemistry. The rhodamine 123
accumulation of the P-glycoprotein (P-gp)-expressing cells
increased up to 46.4, while 2’,7’-bis(2-carboxyethyl)-5(6)-
carboxy-fluorescein acetoxymethyl ester (BCECF-AM)
accumulation of the MRP-expressing cells increased up to 1.6,
in fluorescence activity ratio (FAR). Major P-gp-mediated
efflux pump modifiers are formononetin, amorphigenin,
rotenone and chrysin, while MRP-mediated efflux pump
modifiers are formononetin, afrormosin, robinin, kaempferol
and epigallocatechin. In antiproliferative assay, afrormosin,
amorphigenin, chrysin and rotenone exhibited the strongest
antiproliferative effects in L5178 (max. ID50: 19.70) and
MDA-MB-231 cell lines (max. ID50: 55.47). In a checkerboard
microplate method in vitro, furthermore, the most effective
multidrug resistance (MDR) resistance modifiers,
amorphigenin, formononetin, rotenone and chrysin, were
assayed for their antiproliferative effects in combination with
epirubicin. Rotenone and afrormosin showed additive effects.
Chrysin and amorphigenin on the mouse lymphoma cell line
and formononetin on the MDA-MB-231 cell line synergistically
enhanced the effect of epirubicin.
Multidrug resistance (MDR) is one of the main causes of
failure in the chemotherapeutic treatment of malignant
tumors. Several mechanisms of MDR have been identified
(1). Resistance to numerous anticancer agents is associated
with expression of the 170-kDa P-glycoprotein (P-gp)
(MDR1) and/or the 190-kDa multidrug resistance protein
(MRP). Both belong to the ATP-binding cassette (ABC)
superfamily of membrane transporters (2). P-gp-negative
MDR cells frequently express lung resistance protein (LRP),
related to the major vault protein and believed to be involved
in nucleo-cytoplasmic transport (3). Breast cancer resistance
protein (BCRP) belongs also to the ABC transporter family
of efflux proteins (4). Expression of BCRP is induced by
various chemotherapeutics, such as doxorubicin or
mitoxanthrone, resulting in a drug resistance profile different
from that of other membrane transporters (5).
There is sufficient evidence that diets rich in vegetables
and fruits have cancer-preventive effects (6). Plant-derived
foods are generally good sources of important nutrients
including carotenoids, vitamin C, folate, minerals, fiber and
many less well-characterized bioactive compounds
(phytochemicals). Flavonoids, the most common group of
plant phenolics, are mainly found in citrus fruits, apple skin,
celery, onions, tea, berries, soy and paprika (7). Some
epidemiological studies have suggested that people regularly
drinking several cups of tea a day have a lower risk of breast
cancer. Tea polyphenols are known to inhibit the large multi-
catalytic proteases and metalloproteinases, which are
involved in tumor survival and the formation of metastases
(8). Polyphenols, furthermore, inhibit the activities of tumor-
associated protein kinases and some cancer-related proteins
that regulate DNA replication and tissue transformation (9).
Additionally, certain studies have indicated that one group
of flavonoids, the isoflavones, inhibits the MRP-mediated
efflux in human erythrocytes (10). 
In this study, MRP and MDR efflux pumps were compared
in MDA-MB-231 (HTB-26) human breast cancer cells and
mdr1 gene-transfected mouse lymphoma cells treated with
various flavonoids and isoflavonoids. Furthermore,
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antiproliferative effects and drug synergism with epirubicin
were examined. We report on the modulation of drug
accumulation, antiproliferative activities and drug synergism
in tumor cells by flavonoids and isoflavonoids.
Materials and Methods
Tested compounds. Rotenone, catechin, neohesperidin, naringin,
chrysin, robinin, floretin, floridzin, robinetin, dihydrorobinetin,
kaempferol, dihydrofisetin, dihydroquercetin, sakuranin and
sakuratenin were provided by Sándor Antus, Department of Organic
Chemistry, University of Debrecen, Hungary. Formononetin,
amorphigenin, afrormosin, 6a,12a-dehydroamorphigenin and (+)-
12-hydroxyamorphigenin were provided by Judit Hohmann,
Department of Pharmacognosy, Faculty of Pharmacy, Albert Szent-
Györgyi Medical Center, University of Szeged, Hungary.
Epigallocatechin was purchased from Sigma (St Louis, MO, USA).
All of the tested compounds were dissolved in dimethylsulfoxide
(SERVA, Feinbiochemica, Heidelberg, Germany). 
Cell cultures. The MDA-MB-231 (ATCC: HTB-26) breast cancer
cells were grown in Leibovitz’s L-15 medium with 2 mM L-
glutamine and 10% fetal bovine serum supplemented with
antibiotics. The L5178 mouse T-cell lymphoma cells were
transfected with pHa MDR1/A retrovirus, as previously described
(11). MDR1-expressing cell lines were selected by culturing the
infected cells with 60ng/mL colchicine to maintain the expression
of the MDR phenotype. L5178 (parent) mouse T-cell lymphoma
cells and the human mdr1-transfected subline were cultured in
McCoy's 5A medium supplemented with 10% heat-inactivated
horse serum, L-glutamine and antibiotics. Both cell lines were
cultured at 37ÆC. The mouse lymphoma cell line was maintained
in a 5% CO2 atmosphere; the MDA-MB-231 cell line does not
require CO2.
Immunocytochemistry. The cells were harvested and resuspended
in serum-free medium; the density of the cell suspension was
5x105/mL. One hundred mL was cytocentrifuged for 5 min at
1000 rpm. The samples were fixed in 4ÆC acetone for 10 min and
washed in TBS buffer (pH 7.6) for 5 min. Endogenous
peroxidases were quenched in 0.3% H2O2 for 15 min. The
samples were incubated with primary antibodies (MRP: MRPm6,
monoclonal (ICN) and P-gp: NCL-PGLYm in suitable dilutions
(1:5, 1:10, 1:20) for 1 h at room temperature. The samples were
washed in TBS buffer three times for 5 min and were incubated
with the secondary antibody (DAKO EnVisionì System, CA,
USA) for 30 min. The samples were washed in TBS three times
for 5 min. Diaminobenzidine (DAKO) was used as the
chromogen. The sections were counterstained with hematoxylin
and mounted.
Reversal of MRP drug resistance in the MDA-MB-231 (HTB-26)
cell line. The cells were distributed onto a 6-well plate, each well
containing 2.5x105 cells in 5 mL of culture medium. These cells
were grown for 72 h for the experiment. The culture medium
was then changed to 1 mL of serum-free medium per well and
the tested compounds were added in various amounts (4-40 ÌL)
from a  1.0 mg/mL stock solution. The cells were incubated for
10 min at room temperature. Next, 10 ÌL of 2’,7’-bis(2-
carboxyethyl)-5(6)-carboxy-fluorescein acetoxymethyl ester
(BCECF-AM) (Sigma) was added to the samples to give a final
concentration  of 2.6 ÌM. The cells were incubated for a further
20 min at 37ÆC, washed in phosphate-bufferd saline (PBS) and
detached with trypsin-versen solution [0.25%(w/v) trypsin –
0.03%(w/v) EDTA] to harvest the cells from the 6-well plate.
The cells from each well were transferred to Eppendorf
centrifuge tubes and washed once in culture medium and PBS.
The samples were resuspended in 0.5 mL of PBS for
measurement. The fluorescence of the cell population was
analyzed by flow cytometry using a Beckton Dickinson FACScan
instrument. Indomethacin (Sigma) at a final concentration of 20
ÌM was used as a positive control in the experiments. The
fluorescence activity was determined as the ratio of the
fluorescence activities of treated and untreated samples.
Assay for reversal of MDR in mouse lymphoma cells. The L5178
MDR and L5178Y parent cell lines were grown in McCoy’s 5A
medium containing 10% heat-inactivated horse serum, L-glutamine
and antibiotics. The cells were adjusted to a density of 2x106/mL,
resuspended in serum-free McCoy’s 5A medium and distributed in
0.5-mL aliquots into Eppendorf centrifuge tubes. The tested
compounds were added at various concentrations in different
volumes (2.0-20.0 ÌL) of the 1.0-10.0 mg/mL stock solutions and
the samples were incubated for 10 min at room temperature. Next,
10 ÌL (5.2 ÌM final concentration) of the indicator rhodamine 123
(Sigma) was added to the samples and the cells were incubated for
a further 20 min at 37ÆC, washed twice and resuspended in 0.5 mL
PBS for analysis. The fluorescence of the cell population was
measured with a Beckton Dickinson FACScan flow cytometer.
Verapamil (EGIS, Hungarian Pharmaceutical Company, Budapest,
Hungary) was used as a positive control in the rhodamine 123
exclusion experiments. The percentage mean fluorescence intensity
was calculated for the treated MDR and parental cell lines as
compared with the untreated cells. An activity ratio R was
calculated by the following equation (12), on the basis of the
measured fluorescence values:
MDRtreated/MDRcontrol
R=
parental treated/parental control
Assay for antiproliferative effect. The effects of increasing
concentrations of the drugs alone and their combinations with
resistance modifiers on cell growth were tested in 96-well flat-
bottomed microtiter plates. The compounds were diluted in a
volume of 50 ÌL. Then, 1x104 cells in 0.1 mL of medium were
added to each well, with the exception of the medium control wells.
The culture plates were further incubated at 37ÆC for 72 h; at the
end of the incubation period, 20 ÌL of MTT (thiazolyl blue
tetrazolium bromide, Sigma) solution (from a 5 mg/mL stock) was
added to each well. After incubation at 37ÆC for 4 h, 100 ÌL of
sodium dodecyl sulfate (SDS) (Sigma) solution (10%) was
measured into each well and the plates were further incubated at
37ÆC overnight. The cell growth was determined by measuring the
optical density (OD) at 550 nm (ref. 630 nm) with a Dynatech
MRX vertical beam ELISA reader. Inhibition of cell growth (as a
percentage) was determined according to the formula:
ODsample/ODmediumcontrol
100 – x 100
ODcellcontrol/ODmediumcontrol
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A previously described (13), the checkerboard microplate method
was applied to study the interactions between multidrug resistance
modifiers and epirubicin on the cancer cells.
The effects of the anticancer drug epirubicin and the
multidrug resistance modifiers in combination were studied on
various cancer cell lines. The dilutions of epirubicin (A) were
made in a horizontal direction, and the dilutions of multidrug
resistance modifiers (B) vertically in the microtiter plate in a 100
ÌL volume. The cell suspension in the tissue culture medium was
distributed into each well in 100 ÌL containing 5x104 cells. The
plates were incubated for 48h at 37ÆC in a CO2 incubator. The
cell growth rate was determined after MTT staining and the
intensity of the blue color was measured on a micro ELISA
reader. Drug interactions were evaluated according to the
following system:
FICA = ID50A in combination / ID50A alone
FICB = ID50B in combination / ID50B alone
ID = inhibitory dose
FIC = fractional inhibitory concentration
FIX = FICA+FICB
FIX: 0.51<1 Additive effect
FIX: < 0.5 Synergism
FIX: 1 < 2 Indifferent effect
FIX: > 2 Antagonism
FIX=fractional inhibitory index
Results
The drug accumulation of the human mdr1 gene-transfected
mouse lymphoma and breast cancer cell line carrying MRP
were compared in the presence of naturally-occurring plant-
derived flavonoids and isoflavonoids. 
The presence of MRP on MDA-MB 231 was detected by
immunocytochemistry with MRPm6, monoclonal antibody
(Figure 1). Antibody MRPm6 reacts with an internal
epitope of MRP. It does not cross react with the human
MDR1 and MDR3 gene product. A high level of P-gp
expression was also detected on the membrane of L5178Y
human mdr1 transfected mouse lymphoma cells by NCL-
PGLYm mouse monoclonal antibody that reacts with the
human P-glycoprotein G-terminal cytoplasmic domain
(Figure 2).
Of the isoflavonoids, amorphigenin and formononetin
proved to have the strongest MDR-reversal effects.
Afrormosin, (+)-12a-hydroxyamorphigenin and 6a,12a-
dehydroamorphigenin were moderately effective on the
human mdr1 gene-transfected mouse lymphoma cells
(Table I).
When the same compounds were tested on MRP, the
carboxyfluorescein accumulation of the MDA-MB-231
breast cancer cells was measured. BCECF-AM, a
fluorescent dye used as an intracellular pH indicator, is an
especially good MRP substrate (14). The MRP expression
and its function were assessed by flow cytometry (15),
although the sensitivity of this method was lower than the
rhodamine 123 exclusion test in the mouse lymphoma
cells. Formononetin increased the drug accumulation in
both cell lines as compared with the control. Afrormosin
was only moderately effective on the MRP reversal of the
tumor cells. 6a,12a-Dehydroamorphigenin and (+)-12a-
hydroxyamorphigenin had only marginal effects as
compared with indomethacin-treated MRP cells (Table II). 
When the flavonoids were tested on the drug
accumulation of the breast cancer cells, three groups of
compounds could be distinguished. In the first group,
chrysin, robinin, kaempferol, dihydroquercetin and
epigallocatechin were as effective as the indomethacin
control, elevating the BCECF-AM accumulation by 20-60%.
In the second group, neohesperidin, naringin, floretin,
floridzin, robinetin, dihydrorobinetin and dihydrofisetin
were practically ineffective. In the third group, rotenone,
catechin and sakuranin reduced the drug accumulation in
the cells (Table III). 
When the same flavonoids were tested on the mouse
lymphoma cells, rotenone, chrysin, floretin and
epigallocatechin displayed a dose-dependent increase in the
fluorescence activity ratio (FAR). These compounds caused
a much higher drug accumulation than that of the verapamil
control. Catechin, neohesperidin, naringin, robinin and
sakuratin had moderate effects. Dihydroquercetin,
dihydrofisetin, dihydrorobinetin and floridzin reduced the
rhodamine 123 accumulation in the cells. Kaempferol and
robinetin had no effect on the rhodamine 123 accumulation
of the human mdr1 gene-transfected mouse lymphoma cell
line (Table IV).
As Table V shows, low concentrations of the
isoflavonoids amorphigenin and rotenone inhibited the
cell proliferation or were most toxic on both cell lines.
The breast cancer cells were apparently more sensitive
than the MDR lymphoma cells to the selected
flavonoids. 
In further experiments, the enhanced antiproliferative
activity of combinations of the tested compounds with
epirubicin was examined. Of the resistance modifiers
(formononetin, amorphigenin, rotenone, chrysin and
epigallocatechin), chrysin and amorphigenin were able to
enhance the antiproliferative activity of epirubicin on
mouse lymphoma cells. Although rotenone significantly
increased the rhodamine 123 drug accumulation, it had
only a marginal additive antiproliferative effect in
combination with epirubicin. On the MDA-MB-231 breast
cancer cell line, formononetin and kaempferol exhibited
synergism. Some compounds, e.g. afrormosin and robinin,
also had weak effects in combination with epirubicin.
Interestingly, they were ineffective on the human mdr1
transfected mouse lymphoma cell line. Amorphigenin
treatment likewise resulted in different effects on the two
cell lines (Table VI). 
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Table I. Effects of isoflavonoids on rhodamine 123 accumulation of
human mdr1 gene-transfected mouse lymphoma cell line.
Compounds Ìg/mL Fluorescence 
activity ratio
Verapamil 5 17.1
Formononetin 4 0.8
40 18.3
Amorphigenin 4 12.4
40 46.4
Afrormosin 4 0.5
40 3.1
6a,12a-Dehydroamorphigenin 4 1.1
40 3.0
(+)-12-Hydroxyamorphigenin 4 0.4
40 2.8
DMSO control 0.9
Table II. Effects of isoflavonoids on BCECF-AM accumulation of 
MDA-MB-231 (HTB-26) cell line.
Compounds Ìg/mL Fluorescence 
activity ratio
Indomethacin 10 2.4
Formononetin 4 1.0
40 1.5
Amorphigenin 4 1.0
40 1.0
Afrormosin 4 1.3
40 1.4
6a,12a-Dehydroamorphigenin 4 1.0
40 1.2
(+)-12-Hydroxyamorphigenin 4 1.1
40 1.1
DMSO control 1.0
Figure 1. MRP staining of MDA-MB-231 breast cancer cell line.
Figure 2. MDR1 staining of parental L5178Y mouse lymphoma cells (A)
and its human mdr1 transfected subline (B)
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Table III. Effects of flavonoids on BCECF-AM accumulation of MDA-
MB-231 (HTB-26) cell line.
Compounds Ìg/mL Fluorescence 
activity ratio
Indomethacin 10 1.3
Rotenone 4 0.3
40 0.3
Catechin 4 0.6
40 0.6
Neohesperidin 4 0.8
40 0.9
Naringin 4 1.0
40 0.8
Chrysin 4 1.0
40 1.2
Robinin 4 1.4
40 1.6
Floretin 4 0.7
40 1.0
Floridzin 4 0.8
40 0.9
Robinetin 4 0.8
40 0.9
Dihydrorobinetin 4 0.8
40 1.1
Kaempferol 4 0.9
40 1.3
Dihydrofisetin 4 1.0
40 1.0
Dihydroquercetin 4 0.9
40 1.3
Sakuranin 4 0.8
40 0.7
Sakuranetin 4 0.8
40 0.8
Epigallocatechin 4 1.1
40 1.3
DMSO control 0.9
Table IV. Effect of flavonoids on rhodamine 123 accumulation of human
mdr1 gene-transfected mouse lymphoma cell line.
Compounds Ìg/mL Fluorescence 
activity ratio
Verapamil 5 8.9
Rotenone 4 27.7
40 28.6
Catechin 4 2.7
40 2.9
Neohesperidin 4 2.3
40 2.8
Naringin 4 2.6
40 2.3
Chrysin 4 3.7
40 14.6
Robinin 4 2.0
40 1.5
Floretin 4 0.8
40 4.9
Floridzin 4 0.7
40 0.6
Robinetin 4 0.7
40 0.7
Dihydrorobinetin 4 0.8
40 0.7
Kaempferol 4 0.8
40 0.8
Dihydrofisetin 4 0.7
40 0.5
Dihydroquercetin 4 0.7
40 0.6
Sakuranin 4 0.7
40 0.8
Sakuranetin 4 0.8
40 2.4
Epigallocatechin 4 0.6
40 36.1
DMSO control 0.8
Discussion 
A number of plant extracts and chemically characterized plant
compounds have previously been tested for MDR reversal in
our laboratory (16, 17). In the present study, we examined the
effects of flavonoids and isoflavonoids on the P-gp- and MRP-
mediated MDR mechanisms in mouse lymphoma and human
breast cancer cell lines. Their interactions with the drug
transporters P-gp and MRP, which are frequently expressed in
human tumors, may be of relevance to their use as anticancer
agents, alone or in combination with cytotoxic agents (18, 19).
Differences in the activities of the P-gp and the MRP-mediated
efflux pump were found in the presence of flavonoids and
isoflavonoids. A short-term intracellular drug accumulation and
a long-term viability assay were used to gain insight into various
aspects of the effects of flavonoid compounds on tumor cells.
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Table V. Antiproliferative effects of selected flavonoids and isoflavonoids
on tumor cells.
Compounds MDR cell line MDA-MB-231
ID50 (Ìg/mL) ID50 (Ìg/mL)
Epigallocatechin 1.8 2.6
Rotenone 0.01 0.0005
Kaempferol 55.47 20.59
Robinin 38.51 18.6
Dihydroquercetin 59.32 10.19
Chrysin 15.51 5.61
Formononetin 19.7 17.54
Amorphigenin 1.04 0.01
Afrormosin 48.78 20.5
6a,12a,-Dehydroamorphigenin 9.8 13.51
12a-Hydroxyamorphigenin 2.77 14.04
DMSO 12.5 32.76
Table VI. Antiproliferative effects of selected flavonoids in combination
with epirubicin on tumor cells.
Cell line Samples ID50 FIX Interaction
(Ìg/mL)
L5718 Chrysin 15.51
Epirubicin control 1.4
Chrysin + Epi* 0.606 0.471 synergism
Rotenone 0.01
Epirubicin control 1.4
Rotenone + Epi 0.006 0.604 additive effect
Amorphigenin 1.04
Epirubicin control 3.46
Amorphigenin + Epi 0.18 0.120 synergism
Formononetin 19.7
Epirubicin control 3.46
Formononetin + Epi 3.64 1.230 no interaction
MDA- Amorphigenin 0.01
MB-231 Epirubicin control 0.11
Amorphigenin + Epi 0.01 1.090 no interaction
Formononetin 17.54
Epirubicin control 0.11
Formononetin + Epi 0.02 0.181 synergism
Afrormosin 20.5
Epirubicin control 0.11
Afrormozin + Epi 0.06 0.548 additive effect
Robinin 18.6
Epirubicin control 0.04
Robinin + Epi 0.02 0.501 additive effect
Epigallocatechin 26.01
Epirubicin control 0.05
Epigallo. + Epi 0.05 1.001 no interaction
Kaempferol 55.47
Epirubicin control 0.05
Kaempferol + Epi 0.02 0.440 synergism
Epi* = Epirubicin
Figure 3. Chemical structures of rotenoid derivatives, rotenone and amorphigenin.
In the drug accumulation studies, the P-gp inhibition was
more significant than the MRP inhibition. Furthermore,
some compounds in combination with epirubicin were more
effective than expected on the MRP-expressing human
breast cancer cell line. Thus, the MTT assay allows an
assessment of other cellular effects of the tested
compounds, or these differences can also be explained by
structural and functional mechanisms which might not be
related to P-gp and MRP.
One of the differences between the two efflux systems is
that P-gp has been shown to bind directly the transported
drug to which P-gp confers resistance, whereas MRP
pumps out some compounds through a co-transport
mechanism with reduced glutathione (10, 20, 21). Other
studies have demonstrated that some dietary flavonoids
may modulate organic anion and GSH transport, ATPase
and drug resistance (21). The soybean isoflavone genistein
was found to act as an inhibitor of drug accumulation in
MRP-overexpressing cells (19, 22), and also to interact
with P-gp and inhibit the P-gp-mediated drug transport
(23). However, contradictory results have been reported
concerning the MDR-modulating activity of the flavonoid
polyphenols kaempferol and quercetin, which stimulated
the P-gp-mediated efflux of doxorubicin on the
adriamycin-resistant subline of the MCF-7 breast cancer
cell line (24). 
In our experiments, kaempferol was ineffective in P-gp
inhibition; however, chrysin had a significant inhibitory
effect. Rotenoid derivatives, amorphigenin and rotenone,
had MDR modulating activity, with a structural difference
of hydroxyl(-OH) group at the position of 29th carbon
(Figure 3). The concentrations of the test compounds had
great effects on the outcome of the experiments. A low
concentration of quercetin, for example, activated the
activity of P-gp, whereas a high concentration inhibited that
of P-gp. A similar biphasic effect has been reported for
kaempferol (25). 
It is concluded that the sensitivities of the MDR and
MRP-mediated drug resistance mechanisms to the inhibitory
flavonoids and isoflavonoids differ, based on the chemical
structures, in good agreement with other studies (18, 23).
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